ReCode Therapeutics to receive strategic investment from Cystic Fibrosis Foundation
The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said: